Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b in hydroxyurea-resistant/intolerant essential thrombocythemia
NCT06552429Phase 2Recruiting
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in essential thrombocythemia (ET), sponsored by Xiamen Tebao Biological Engineering Co., Ltd.. Started Aug 2024; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT06552429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552429.